Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
- Conditions
- Advanced Ovarian Cancer
- Registration Number
- NCT04135521
- Lead Sponsor
- Far Eastern Memorial Hospital
- Brief Summary
To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
- Detailed Description
Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II\~IV), who had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were included in the study. Patient characteristics, any treatment related side-effects (peri-operative and post-operative complications, chemotherapy related adverse events), treatment response (complete or partial response, stable disease or progressive disease), post-treatment surveillance (disease status: disease-free, recurrence or cancer-related death) will be recorded. Univariate and multivariate logistic regression analysis will be employed to evaluate the survival benefit of the two different chemotherapy methods.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 50
- Women with FIGO stage II~IV ovarian cancer
- At least one cycle of intravenous dose-dense or intraperitoneal chemotherapy had been administered as the front-line chemotherapy.
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups 10 years months
- Secondary Outcome Measures
Name Time Method Overall survivals between this two groups 10 years months
Trial Locations
- Locations (1)
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
🇨🇳Banqiao, New Taipei, Taiwan